Inflammation during prostate needle biopsy protects against prostate cancer
Inflammation during prostate needle biopsies (PNB) is associated with a significantly lower risk of prostate cancer, a recent meta-analysis has shown.
Pooled analysis of 25 studies showed that the presence of any inflammation during PNB was significantly associated with a lower risk of prostate cancer (odds ratio [OR], 0.455; 95 percent CI, 0.337–0.573). Significant heterogeneity was reported (p<0.001).
Four studies assessed acute inflammation during PNB and found a similar protective effect against prostate cancer (OR, 0.681; 0.450–0.913). No significant heterogeneity was observed (p=0.223).
Fifteen studies with significant heterogeneity (p<0.001) evaluated the effect of chronic inflammation during PNB. Pooled analysis showed a significant correlation with a lower risk of prostate cancer (OR, 0.499; 0.334–0.665).
Prostate cancer in the same PNB specimen was evaluated in 13 studies which showed the same protective effect of inflammation (OR, 0.363; 0.245–0.480). In comparison, the effect of inflammation on prostate cancer in different PNB specimens was assessed in 12 studies. A similar trend was observed (OR, 0.560; 0.329–0.791).
“Inflammation is a hallmark of immune system upregulation and thus it is plausible that it favours the host’s defense mechanisms with a lower risk of prostate cancer in the current study. Our results implicate inflammation and immunomodulation as candidate targets for pharmacologic intervention to prevent and potentially treat prostate cancer,” explained researchers.
For the present meta-analysis, researchers searched the databases of Web of Science, PubMed and Embase for studies that investigated the influence of inflammation during PNB on histologically-confirmed prostate cancer.